The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months. Who: Dr. Lucinda Bateman, Located in Salt
Help advance biomarker research! The Bateman-Horne Center is actively recruiting patients and healthy controls who are eager to participate by providing samples and information. This is then used in ME/CFS and FM research to discover biomarkers, improve diagnosis, and advance treatment.